Cytokinetics Quarterly Cash Flow Statement
NASDAQ: CYTKHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Cytokinetics free cash flow
In the quarter ended Jun 30, 2026, Cytokinetics generated -$159.8 million of operating cash flow and spent $4.3 million on capital expenditures. That left free cash flow of -$164.2 million, a free-cash-flow margin of -573.6% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Cytokinetics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -198.76M | -206.03M | -183.03M | -306.18M | -134.37M | -161.38M | -150.02M | -160.54M | -143.32M | -135.64M | -136.90M | -129.42M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 3.63M | 3.38M | 2.86M | 2.68M | 2.29M | 2.30M | 2.38M | 2.41M | 2.41M | 2.33M | 6.33M | 1.85M |
| Stock-Based Compensation | 35.71M | 30.39M | 30.51M | 30.70M | 27.54M | 23.55M | 26.25M | 25.36M | 24.62M | 21.61M | 19.49M | 18.72M |
| Change in Working Capital | -19.43M | 4.77M | 5.91M | 27.36M | -47.13M | -4.68M | 43.50M | 11.46M | 11.36M | -22.05M | 49.59M | 4.22M |
| Operating Cash Flow | -159.84M | -145.46M | -142.65M | -107.50M | -128.24M | -131.62M | -65.57M | -101.50M | -99.31M | -129.51M | -74.04M | -96.20M |
| Capital Expenditures | -4.33M | -5.93M | -5.64M | -9.35M | -4.14M | -5.66M | -1.29M | -701.00K | -1.92M | 0 | -77.00K | -220.00K |
| Investing Cash Flow | -507.00M | 145.49M | -71.19M | -70.98M | 52.88M | 105.96M | 110.86M | -45.05M | -651.55M | 32.64M | -81.41M | 73.04M |
| Debt Repaid | -3.59M | -2.73M | -2.72M | -2.71M | -2.70M | -2.68M | -2.67M | -2.66M | -2.65M | -705.00K | 0 | 0 |
| Financing Cash Flow | 792.86M | 7.77M | 110.70M | 330.47M | 78.53M | 4.75M | 2.38M | 3.42M | 821.01M | 103.79M | 168.80M | 54.22M |
| Net Change in Cash | 125.42M | 7.32M | -102.95M | 152.03M | 2.50M | -21.18M | 47.97M | -143.25M | 70.17M | 6.95M | 13.33M | 31.05M |
| Free Cash Flow | -164.17M | -151.39M | -148.29M | -116.86M | -132.38M | -137.28M | -66.86M | -102.20M | -101.23M | -129.51M | -74.11M | -96.42M |
This table shows 12 quarterly periods of Cytokinetics's cash flow statement, from Q2 2026 back to Q3 2023, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow CYTK's reporting calendar. What is a cash flow statement?